On December 21st, the Ukrainian Parliament voted in favor of legalizing medical cannabis, following a war with Russia that has resulted in thousands of people suffering from post-traumatic stress disorder. Many believe that this condition can be alleviated through medication, according to a report by the Associated Press.
The new law will come into effect six months from now, allowing for the scientific and industrial use of marijuana. It was passed in the Kiev Parliament with 248 votes out of the 401 seats. Details of the voting were not provided at the time. The law was proposed by Prime Minister Denys Smyhal.
The possibility of legalizing medical cannabis has been a long-standing debate in Ukraine. Many people endorse the benefits of cannabis for medical treatment, while others express concerns that legalizing medical marijuana may result in an influx of drugs into Ukrainian urban streets.
The measure imposes strict control over the production and sale of marijuana. Any medication containing cannabis derivatives requires a prescription from a doctor. The recreational use of marijuana remains classified as a criminal offense.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
